{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:43:00Z","timestamp":1759365780989,"version":"build-2065373602"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1DA049415","UM1DA049415","UM1DA049415","UM1DA049415","UM1DA049415","UM1DA049415","UM1DA049415","UM1DA049415"],"award-info":[{"award-number":["UM1DA049415","UM1DA049415","UM1DA049415","UM1DA049415","UM1DA049415","UM1DA049415","UM1DA049415","UM1DA049415"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The HEALing Communities Study was a multi-site cluster randomized waitlist-controlled trial evaluating a community-engaged, data-driven intervention to select and deploy evidence-based practices (EBPs) including overdose education and naloxone distribution (OEND), medication for opioid use disorder (MOUD), and safer opioid prescribing. The trial was conducted in 67 highly impacted communities in 4 states, including 8 Rural and 8 urban communities in New York State (NYS). To inform future community-level decision making, we estimated the implementation costs of the EBPs selected by NYS communities.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The study was implemented between January 2020-June 2022 (Wave 1, 30 months duration including the peak COVID-19 emergency period) and July 2022-December 2023 (Wave 2, 18 months); each wave included 4 Rural and 4 urban NYS communities. We collected cost data prospectively using invoices, administrative records, and interviews with program staff and stakeholders. We then conducted a micro-costing analysis from the community perspective and compared costs from Waves 1 and 2.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>In both Waves, each community deployed on average 15 EBPs (range 8\u201325). EBP costs averaged $705,000 (range $320,000-$1.3\u00a0million) and $312,000 (range $39,200-$686,300) in Waves 1 and 2, respectively. In Wave 1, 25% of costs were allocated for OEND, 71% for MOUD, and 4% for safer prescribing, compared to 38% for OEND, 60% for MOUD, and 2% for safer prescribing in Wave 2. Average EBP costs per community were $147,600 (range $20,900-$374,000) for those in the OEND category, $345,400 (range $4,100-$1.1\u00a0million) for MOUD, and $16,400 (range $360-$105,500) for safer prescribing. Total EBP cost per capita in urban communities was $0.32 compared to $2.65 in Rural communities in Wave 1, and $0.41 urban communities compared to $0.65 in Rural communities in Wave 2.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The lower EBP costs in Wave 2 resulted from differences in EBP categories and specific EBPs selected and may also reflect differences in the duration of the intervention and the impact of the COVID-19 pandemic over time. Higher per capita costs in rural communities indicate that many costs were not directly related to the number of individuals served.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13722-025-00606-6","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T10:22:05Z","timestamp":1759314125000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost of implementing evidence-based practices to reduce opioid overdose fatalities in New York State communities"],"prefix":"10.1186","volume":"20","author":[{"given":"Jazmine M.","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dawn","family":"Gruss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"David","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Rodgers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nabila","family":"El-Bassel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce R.","family":"Schackman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura E.","family":"Starbird","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,1]]},"reference":[{"key":"606_CR1","doi-asserted-by":"crossref","unstructured":"Spencer MR, Mini\u00f1o AM, Warner M. Drug overdose deaths in the United States, 2001\u20132021. NCHS Data Brief, no 457 [Internet]. 2022 [cited 2024 Jun 25]. Available from: https:\/\/www.cdc.gov\/nchs\/products\/databriefs\/db457.htm","DOI":"10.15620\/cdc:122556"},{"key":"606_CR2","unstructured":"U.S. Overdose Deaths Decrease in 2023, First Time Since 2018 [Internet]. [cited 2024 Oct 29]. Available from: https:\/\/www.cdc.gov\/nchs\/pressroom\/nchs_press_releases\/2024\/20240515.htm"},{"key":"606_CR3","doi-asserted-by":"crossref","unstructured":"Garnett M, Mini\u00f1o A, Joyce M, Driscoll A, Valenzuela C. Drug overdose deaths in the united states, 2003\u20132023. Atlanta, GA: Centers for Disease Control and Prevention; 2024","DOI":"10.15620\/cdc\/170565"},{"key":"606_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108326","volume":"217","author":"L Sprague Martinez","year":"2020","unstructured":"Sprague Martinez L, Rapkin BD, Young A, Freisthler B, Glasgow L, Hunt T, et al. Community engagement to implement evidence-based practices in the HEALing communities study. Drug Alcohol Depend. 2020;217:108326.","journal-title":"Drug Alcohol Depend"},{"key":"606_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108335","volume":"217","author":"HEALing Communities Study Consortium","year":"2020","unstructured":"HEALing Communities Study Consortium. The HEALing ( Helping to end Addiction Long-term SM) communities study: protocol for a cluster randomized trial at the community level to reduce opioid overdose deaths through implementation of an integrated set of evidence-based practices. Drug Alcohol Depend. 2020;217:108335.","journal-title":"Drug Alcohol Depend"},{"key":"606_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108336","volume":"217","author":"AP Aldridge","year":"2020","unstructured":"Aldridge AP, Barbosa C, Barocas JA, Bush JL, Chhatwal J, Harlow KJ, et al. Health economic design for cost, cost-effectiveness and simulation analyses in the HEALing Communities tudy. Drug Alcohol Depend. 2020;217:108336.","journal-title":"Drug Alcohol Depend"},{"key":"606_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2023.109804","volume":"245","author":"R Chandler","year":"2023","unstructured":"Chandler R, Nunes EV, Tan S, Freeman PR, Walley AY, Lofwall M, et al. Community selected strategies to reduce opioid-related overdose deaths in the HEALing (Helping to end addiction long-term SM) Communities Study. Drug Alcohol Depend. 2023;245:109804.","journal-title":"Drug Alcohol Depend"},{"key":"606_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108325","volume":"217","author":"T Winhusen","year":"2020","unstructured":"Winhusen T, Walley A, Fanucchi LC, Hunt T, Lyons M, Lofwall M, et al. The opioid-overdose reduction continuum of care approach (ORCCA): evidence-based practices in the HEALing Communities Study. Drug Alcohol Depend. 2020;217:108325.","journal-title":"Drug Alcohol Depend"},{"issue":"11","key":"606_CR9","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2401177","volume":"391","author":"JH Samet","year":"2024","unstructured":"HEALing Communities Study Consortium, Samet JH, El-Bassel N, Winhusen TJ, Jackson RD, Oga EA, et al. Community-based cluster-randomized trial to reduce opioid overdose deaths. N Engl J Med. 2024;391(11):989\u20131001.","journal-title":"N Engl J Med"},{"key":"606_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2025.112671","volume":"272","author":"JA Barocas","year":"2025","unstructured":"HEALing Communities Study Consortium, Barocas JA, Aldridge A, Adkins KF, Barbosa C, Battaglia TA, et al. An economic analysis of community costs incurred to implement the Communities That HEAL intervention to reduce opioid overdose deaths in four states. Drug Alcohol Depend. 2025;272:112671.","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"606_CR11","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/s11121-011-0259-9","volume":"13","author":"MR Kuklinski","year":"2012","unstructured":"Kuklinski MR, Briney JS, Hawkins JD, Catalano RF. Cost-benefit analysis of communities that care outcomes at eighth grade. Prev Sci. 2012;13(2):150\u201361.","journal-title":"Prev Sci"},{"issue":"2","key":"606_CR12","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s11292-014-9226-3","volume":"11","author":"MR Kuklinski","year":"2015","unstructured":"Kuklinski MR, Fagan AA, Hawkins JD, Briney JS, Catalano RF. Benefit-Cost analysis of a randomized evaluation of communities that care: monetizing intervention effects on the initiation of delinquency and substance use through grade 12. J Exp Criminol. 2015;11(2):165\u201392.","journal-title":"J Exp Criminol"},{"key":"606_CR13","unstructured":"Substance Abuse and Mental Health Services Administration. Opioid-Overdose Reduction Continuum of Care Approach (ORCCA) Practice Guide. [cited 2024 Aug 5]; Available from: https:\/\/store.samhsa.gov\/sites\/default\/files\/pep23-06-01-001.pdf"},{"key":"606_CR14","volume":"32","author":"A Davis","year":"2024","unstructured":"Davis A, Knudsen HK, Walker DM, Chassler D, Lunze K, Westgate PM, et al. Effects of the Communities That HEAL (CTH) intervention on perceived opioid-related community stigma in the healing communities study: results of a multi-site, community-level, cluster-randomized trial. Lancet Reg Health. 2024;32:100710.","journal-title":"Lancet Reg Health"},{"issue":"3","key":"606_CR15","doi-asserted-by":"publisher","first-page":"179","DOI":"10.2165\/00019053-200927030-00001","volume":"27","author":"D Polsky","year":"2009","unstructured":"Polsky D, Glick H. Costing and cost analysis in randomized controlled trials: caveat emptor. Pharmacoeconomics. 2009;27(3):179\u201388.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"606_CR16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/ADM.0000000000001218","volume":"18","author":"Y Tin","year":"2024","unstructured":"Tin Y, Castry M, Bowers-Sword R, Shantharam S, Aldridge A, Zarkin GA, et al. Establishing a protocol for determining the costs of an integrated set of evidence-based practices aimed at reducing opioid overdose deaths. J Addict Med. 2024;18(1):13\u20138.","journal-title":"J Addict Med"},{"key":"606_CR17","unstructured":"Bureau of Labor Statistics. U.S. Department of Labor. Occupational Employment and Wage Statistics [Internet]. [cited 2024 Jul 15]. Available from: http:\/\/www.bls.gov\/oes\/"},{"key":"606_CR18","unstructured":"New York State Department of Health. New York State\u2019s Opioid Overdose Prevention Program [Internet]. 2023 [cited 2024 Aug 27]. Available from: https:\/\/www.health.ny.gov\/diseases\/aids\/general\/opioid_overdose_prevention\/"},{"key":"606_CR19","unstructured":"Home -. MATTERS Network [Internet]. [cited 2024 Aug 27]. Available from: https:\/\/mattersnetwork.org\/"},{"issue":"4","key":"606_CR20","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1111\/jrh.12743","volume":"39","author":"C Carpenedo Mun","year":"2023","unstructured":"Carpenedo Mun C, Schuler H, Baker R, Byrne F, Bresani E, Meyers K. Rural communities face more than an opioid crisis: reimagining funding assistance to address polysubstance use, associated health problems, and limited rural service capacity. J Rural Health. 2023;39(4):795\u2013803.","journal-title":"J Rural Health"},{"key":"606_CR21","unstructured":"Rural. and Urban Health | Health Policy Institute | Georgetown University [Internet]. [cited 2024 Oct 29]. Available from: https:\/\/hpi.georgetown.edu\/rural\/"},{"issue":"2","key":"606_CR22","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1001\/jama.2024.7012","volume":"332","author":"L Beletsky","year":"2024","unstructured":"Beletsky L, Tiako MJN. Costs and essential drug access\u2014the case of Naloxone. JAMA. 2024;332(2):109.","journal-title":"JAMA"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-025-00606-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-025-00606-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-025-00606-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T10:22:08Z","timestamp":1759314128000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-025-00606-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["606"],"URL":"https:\/\/doi.org\/10.1186\/s13722-025-00606-6","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,1]]},"assertion":[{"value":"28 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data collection for this study was carried out with relevant guidelines set forth by the study protocol. This study protocol (Pro00038088) was approved by Advarra Inc., the HEALing Communities Study single Institutional Review Board. All subjects agreed to participate and provided verbal informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"77"}}